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Hyperactivity of Mek in TNS1 knockouts leads to
potential treatments for cystic kidney diseases
Zong-Ye Wu1, Chun-Lung Chiu1, Ethan Lo1, Yuh-Ru Julie Lee 2, Soichiro Yamada3 and Su Hao Lo1
Abstract
Cystic kidney disease is the progressive development of multiple fluid-filled cysts that may severely compromise
kidney functions and lead to renal failure. TNS1 (tensin-1) knockout mice develop cystic kidneys and die from renal
failure. Here, we have established TNS1-knockout MDCK cells and applied 3D culture system to investigate the
mechanism leading to cyst formation. Unlike wild-type MDCK cells, which form cysts with a single lumen, TNS1-
knockout cysts contain multiple lumens and upregulated Mek/Erk activities. The multiple lumen phenotype and Mek/
Erk hyperactivities are rescued by re-expression of wild-type TNS1 but not the TNS1 mutant lacking a fragment
essential for its cell–cell junction localization. Furthermore, Mek inhibitor treatments restore the multiple lumens back
to single lumen cysts. Mek/Erk hyperactivities are also detected in TNS1-knockout mouse kidneys. Treatment with the
Mek inhibitor trametinib significantly reduces the levels of interstitial infiltrates, fibrosis and dilated tubules in TNS1-
knockout kidneys. These studies establish a critical role of subcellular localization of TNS1 in suppressing Mek/Erk
signaling and maintaining lumenogenesis, and provide potential therapeutic strategies by targeting the Mek/Erk
pathway for cystic kidney diseases.
Introduction
Cystic kidney disease is a group of renal disorders that
cause abnormal fluid-filled cysts. These diseases may be
acquired from chronic renal defects or inherited due to
gene mutations. The most frequent form of cystic kidney
disease is the inherited polycystic kidney disease (PKD),
which is a common cause of end stage renal disease
(ESRD)1. Two common types of PKD are autosomal
dominant polycystic kidney disease (ADPKD) and auto-
somal recessive polycystic kidney disease (ARPKD).
ADPKD often results from mutations in PKD1 or PKD2
genes and patients usually develop signs and symptoms
between the ages of 30 and 40. ARPKD is a rarer disease
caused by mutations in the PKHD1 gene and often leads
to fetal or neonatal death1,2. Despite differences in the age
of onset, disease severity, and cyst distribution of various
PKDs, cyst formation commonly results from dysregu-
lated cell proliferation and/or apoptosis, increased secre-
tion into tubular lumen, abnormal cell–cell or cell–matrix
interactions, loss of cellular polarity, and cilium dysfunc-
tion3. The critical roles of these events are supported by
numerous studies, including phenotypic characterizations
of genetically engineered mouse models4 and cyst for-
mation studies using Madine-Darby Canine Kidney
(MDCK) cells in 3-dimensional (3D) culture systems5–7.
However, no effective treatment to prevent or slow down
PKD progression in patients is currently available.
The human tensin family consists of four members
(tensin-1, tensin-2, tensin-3, and cten) that all reside at focal
adhesions8,9. Tensin-1 (TNS1) is also localized to cell–cell
junctions10. All tensins contain two domains at their C-
termini: the Src homology 2 (SH2) and phosphotyrosine
binding (PTB) domains. Their PTB domains bind to
β-integrin NPXY motifs and this direct interaction is
required for maintaining β1-integrin activity11, which is
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essential for many cellular events, including cell adhesion,
migration, and proliferation. The SH2 domains bind to
phosphotyrosine-containing proteins, such as EGFR, c-Met,
Axl, Src, Fak, p130cas, and paxillin8,12–15 and transduce
signaling cascades mediated by protein tyrosine kinases.
Tensins also regulate small GTPase signaling pathways by
binding to the Rho GTPase-activating protein DLC1
(deleted in liver cancer 1)16–18 or Dock5, a guanine
nucleotide exchange factor for the GTPase Rac19,20. Addi-
tionally, TNS1 interacts with actin filaments and modulates
the actin cytoskeleton network21. These interactions pro-
vide molecular linkages between integrin receptors and the
actin cytoskeleton and also mediate multiple signaling
transduction pathways. These pathways modulate a host of
biological events including cell adhesion, migration, pro-
liferation, apoptosis, and differentiation8,9,19,22.
The role of TNS1 in the kidney has been illustrated in
TNS1 knockout (KO) mouse studies. TNS1-KO kidneys
are clinically and histologically normal for the first
2–3 months, then they start developing interstitial fibro-
sis, infiltrates, tubular dilations, and higher BUNs23. The
renal conditions grow progressively worse, and mice die at
around 10–18 months old. Cysts are only found in the
kidneys but not in other tissues. However, TNS1-KO mice
also develop enlarged posterior mitral leaflets with
abnormal collagen and proteoglycan deposits24. These are
characteristic features of nonsyndromic mitral valve pro-
lapse (MVP), a common degenerative cardiac valvopathy.
This finding validates the genome-wide association stu-
dies that have identified TNS1 as a risk locus for MVP24.
Coincidentally, MVP and mitral regurgitation are very
common in PKD patients25,26. Despite all these findings,
the molecular mechanism leading to the formation of
cystic kidneys and eventual renal failure caused by TNS1
deficiency remains unclear.
In this study, we have generated an in vitro TNS1-KO
MDCK cell system to determine the molecular mechan-
ism leading to cyst formation and validated the in vitro
results in KO mice. With the obtained findings, we further
investigated the potential therapeutic strategy for cystic
kidney diseases using TNS1-KO mice.
Materials and methods
Reagents
Rabbit anti-TNS1 antibody was generated against human
TNS1 aa1328–1339 peptide16. Antibodies against E-
cadherin (#9121), pMEK1/2(S221) (#2338), pMEK1/2
(S217/221) (#9154), Mek1/2 (#9122), pERK1/2(T202Y204)
(#9101), ERK1/2 (#9194), pAkt(S473) (#9271), Akt (#9272),
pGSK3β(S9) (#5558), and GSK3β (#12456) were from Cell
Signaling Technology. Anti-GAPDH (#CB1001) was from
Millipore. Anti-Vinculin (#693291) was from MP Biome-
dical. Anti-mouse or rabbit IgG HRP conjugated secondary
antibodies (#7076, #7074) were from Cell Signaling
Technology. Alexa Fluor secondary antibodies (488/594)
and Alexa Fluor 488/594 Phalloidin were from Thermo
Scientific and anti-GP135/Podocalyxin (#3F2/D8) was
from the Developmental Studies Hybridoma Bank at the
University of Iowa. VECTASHIELD antifade DAPI
mounting solution was from Vector Labs. Mek inhibitors
CI-1040 (#S1020), selumetinib (#S1008), trametinib
(#S2673) were from Selleckchem, and PD98059 (#9900),
U0126 (#9903) were from Cell Signaling Technology.
Plasmids, DNA transfection, and cell culture
All constructs were generated using Gibson assembly
cloning and were confirmed by DNA sequencing. The
plasmid DNA was transfected into cells with Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
protocol. For subcellular localization studies, cells were
harvested 24 h post-transfection for analysis. For estab-
lishing TNS1-KO cells, MDCK cells from ATCC were co-
transfected with the Cas9 vector carrying TNS1 guide
sequence (5′-ACCTGGTGTACGTCACGGAG-3′) and
the donor vector containing puromycin selection cassette
flanked by 5′ and 3′TNS1 homologous regions. After
transfection, cells were passaged 7 times at a dilution of
1:10 (about 23 days post transfection), then cells were
treated with 5 µg/ml puromycin. Stable clones were iso-
lated and expended for further validation and analysis.
Stable TNS1-KO MDCK cells were maintained in com-
plete medium (Dulbecco’s Modified Eagle Medium con-
taining glutamine, 4 g/L glucose, 10% fetal bovine serum,
and 1% penicillin–streptomycin) supplemented with 2 µg/
ml puromycin. To re-introduce wild-type TNS1 or TNS1
mutants into TNS1-KO MDCK cells, GFP-TNS1, tdTo-
mato-TNS1, tdTomato-TNS1Δ882–1032 fusion plasmids
were transfected into KO cells. Cells were selected against
750 µg/ml G418 sulfate. Stable clones were maintained in
complete medium containing 250 µg/ml G418 sulfate and
2 µg/ml puromycin.
3D Culture and analysis
For 3D culture, each well of eight well chamber slides
(#154534, Lab-Tek) was precoated with 10 µl of 100% low
growth factor Matrigel (#35623, Corning). Five thousand
cells suspended in complete media containing 2% Matri-
gel with or without Mek inhibitor were plated onto each
well and then incubated at 37 °C with 5% CO2 for 5 days
with cell media changed every 2–3 days. During this time,
cells developed into cysts and were either used for protein
isolation or fixed with 4% paraformaldehyde for mor-
phological analysis or immunofluorescence staining.
Cysts were grouped into three different phenotype
categories: single, multiple, and filled lumens. Single
lumen cysts were cysts contain one central lumen. Cysts
containing multiple lumens displayed many lumens of
varying sizes or with one large lumen plus two or more
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smaller lumens. Cysts with no apparent lumen were
classified as cysts containing filled lumens. For statistical
analysis, more than 80 individual 3D cysts were counted
for each sample in the experiment. Average phenotype
percentage ratios of more than three experiments were
calculated and p-values were obtained by two-tailed t test
with equal variance.
To compare cyst size between samples, average of ver-
tical and horizontal diameters of 3D cysts were calculated
(n > 30 for each sample) and p-values calculated using
two-tailed t-test with equal variance.
Immunofluorescence and immunohistochemical staining
Cells grown on coverslips or in 3D Matrigel were fixed
in 4% PFA permeabilized with 0.1% Triton X-100. Pri-
mary antibodies were applied to samples on coverslips or
in the chamber wells and incubated at 4 °C overnight.
After several washes, samples were incubated with sec-
ondary antibodies or phalloidin tagged with fluorescence.
Images were taken using LSM 500 confocal microscope
from Zeiss. Multiple Z sections of the cysts are taken for
each 3D spheroid, with stack distance of 0.5 µm taken for
each Z stack.
For live-cell imaging of GFP-actin transformed MDCK
cells transfected with various tdTomato-TNS1 mutants,
images were collected by a Zeiss AxioObserver equipped
with a Yokogawa CSU-10 spinning disk confocal system,
488 and 561 nm solid-state lasers, and a Photometrics
CoolSNAP HQ camera.
The kidney sections were de-paraffinized in xylene and
rehydrated in graded alcohol and water. An antigen
retrieval step (10 nM sodium citrate (pH 6.0) at a sub-
boiling temperature) was used for each primary antibody.
Endogenous peroxidase activity was blocked by 3%
hydrogen peroxide, followed by blocking serum and sec-
tions were incubated with primary antibodies overnight at
4 °C. Detection of immunostaining was carried out by
using the VECTASTAIN® ABC system, according to the
manufacturer’s instructions (Vector Laboratories).
Protein lysate preparation and immunoblot analysis
Cysts grown in Matrigel were recovered using Cell
Recovery Solution (Corning) to dissolve the extracellular
matrices and then were lysed in ice-cold lysis buffer
(20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate, 1 mM Na3VO4, 1 μg/ml leu-
peptin, and protease/phosphatase inhibitor cocktail
(Roche)) for total protein preparation. Frozen kidneys
were first homogenized using a 2-ml Dounce homo-
genizer (Wheaton) in lysis buffer. Cell/tissue lysates were
centrifuged at 14,000 RPM for 15 min at 4 °C and super-
natant portions were collected for immunoblotting
analysis. Protein concentrations were measured with
Protein Assay Dye Reagent Concentrate (Bio-Rad).
For immunoblot analysis, proteins were separated on an
SDS-PAGE gel and transferred to nitrocellulose mem-
brane (Bio-Rad). Membranes were incubated in blocking
buffer (5% non-fat milk) for 1 h and then with primary
antibodies overnight at 4 °C. After several washes, mem-
branes were incubated with secondly antibodies for 1 h at
room temperature. The signals were detected by using
enhanced chemiluminescence (ECL) reagents (Advansta)
and AzureBiosystems C400 chemiluminescent imaging
system.
Mouse studies
TNS1-KO mice were generated as described23. Trame-
tinib in corn oil (Sigma-Aldrich) was orally administrated
to 3-month-old TNS1-KO and WT mice at 1 mg/kg once
daily for 14 days. Four days after the last treatment, mice
were euthanized, and kidneys were fixed in 4% paraf-
ormaldehyde buffered solution and processed for gross
morphological examination, H&E, Sirius Red, and
immunohistochemical staining. A portion of the kidney
tissues was flash frozen in liquid nitrogen and immedi-
ately stored at −80 °C for RNA and protein extraction. At
least 4 male mice each group were randomizedly chosen
for studies. N= 4 is derived from power analysis using the
one-sample binomial one-sided exact test in DSTPLAN in
order to achieve the design parameters of a significance
level of α= 0.05 with 80% power. All mouse studies were
performed according to protocols approved by institu-
tional animal care and use committees of the University of
California-Davis. Animals were maintained in specific
pathogen-free environments.
Quantification of inflammatory cell infiltration and
immunohistochemical signals
Ten random photographs from hematoxylin and eosin
(H&E)–stained kidney sections were taken at a magnifi-
cation of ×200 using an Olympus BX40 microscope with
an Olympus DP-72 camera. Inflammatory cell infiltration
was evaluated semi-quantitatively by a pathologist blinded
to group assignment (arbitrary inflammation score 0–3,
where 0= no change; 1=mid; 2=moderate and 3=
severe).
To quantify the immunohistochemical signals from
each kidney section, ten random photographs were taken
at a magnification of ×100 (Sirius red) or ×200 (pMek,
MeK, pERK). These images were analyzed and quantified
by ImageJ software version 1.48 as described27.
Statistical analysis
Data were presented either as the mean ± SD or the mean
± SE of at least three independent experiments. All
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experimental results were included for statistical analysis
unless the experiments were not completed successfully,
for example mice die unexpectedly, transfection was not
successful, or protein gel was not loaded equally. The
quantitative in vitro and in vivo data were analyzed using
the student’s t-test. All analyses were performed using
SPSS software (v20.0; SPSS, Inc., Chicago, IL). All statis-
tical tests were two-sided and P-values < 0.05 were con-
sidered statistically significant.
Results
Generation and validation of TNS1-KO MDCK cells
To determine mechanistic insights of the polycystic for-
mation in TNS1-KO kidney, we opted to establish an
in vitro system and generate MDCK TNS1-KO cells by
CRISPR-Cas9 and homology-directed repair (HDR)
methodology. The Cas9 vector containing a TNS1 guide
sequence targeting the exon encoding the start ATG site of
TNS1 and the donor vector containing the promoter-less
GFP reporter and puromycin selection cassette flanked by
5′ and 3′ TNS1 homologous regions, were co-transfected
into MDCK cells (Fig. 1a). After 7 passages to dilute out the
Cas9 vector, puromycin was applied to select stable clones.
Individual stable clones were isolated and analyzed for
TNS1 expression by immunoblotting (IB), RT-PCR, and
immunofluorescence (IF) staining. The lack of 220kD
TNS1 protein, mRNA, and the focal adhesion staining
pattern (Fig. 1b–d) demonstrate that we have successfully
generated MDCK TNS1-KO cells. However, GFP was not
detected in any of TNS1-KO stable clones, suggesting that
the endogenous TNS1 promoter did not initiate the tran-
scription of GFP gene and/or the level of GFP product was
too low to be detected.
Loss of TNS1 leads to multiple lumen phenotype but
maintains the apical-basal polarity in MDCK 3D culture
To investigate TNS1′s role in 3D cyst development,
MDCK TNS1-WT or KO cells were cultured in Matrigel
for 5 days. Compared to WT cells which predominantly
form 3D cysts containing one hollow lumen, cysts from
TNS1-KO cells consisted of two or more smaller lumens
(Fig. 2a–c), which were more apparent from the 3D
reconstruction of confocal Z-stack images (Fig. 2b). Fur-
thermore, quantification comparing the diameters of
MDCK TNS1-WT and KO cysts revealed that cysts that
lack of TNS1 were significantly larger than WT cysts (KO
vs WT= 64 ± 5.9 vs 52 ± 7.2 μm) (Fig. 2d). Immuno-
fluorescence analysis showed that although forming mul-
tiple lumens, TNS1-KO cysts still developed apical-basal
polarities as judged by GP135 (apical surface marker) and
E-cadherin (lateral membrane marker) staining (Fig. 2a).
To examine the onset of multiple lumen formation,
MDCK cells grown in Matrigel were harvested at earlier
time points for immunofluorescent staining using
antibodies against GP135/podocalyzin and E-cadherin. In
WT cells, GP135 was initially localized at the basal surface
from 3 to 24 h and was then relocated to the newly formed
Fig. 1 Generation and validation of TNS1-KO MDCK cells.
a Schematic diagram of the generation of TNS1-KO cells by using two
vectors CRISPR/Cas9 and homology-directed repair technology. The
guide plasmid containing the TNS1 target sequence and Cas9 coding
sequence and the donor vector were co-transfected into cells. The
guide plasmid created a double-stranded break at the target site of
TNS1. The donor vector contains about 600 bp homologous to the 5′
and 3′ flanking region of exon1 and is used as template for DNA repair
by homologous recombination, resulting in replacement of TNS1
exon1, which contains the first ATG site, with the donor cassette that
includes promoter-less GFP, PGK promotor and the puromycin
selection gene flanked with loxP sites. MDCK WT or KO cells were
lysed or fixed for immunoblotting (b), RT-PCR (c), or
immunofluorescence (d) assays, respectively. Immunoblotting by
TNS1 antibody detected 220kD TNS1 protein in WT but not any of the
four KO clones. KO1 clone was used for further analysis. TNS1 mRNA
was only presented in WT cells. Immunofluorescence staining showed
co-localizations of TNS1 and vinculin at focal adhesion sites (arrows) in
WT but not in KO cells. Nuclear stainings shown in WT and KO1 with
TNS1 antibody were likely due to the secondary antibody. Scale bar=
10 μm.
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single apical membrane initiation site (AMIS) between 24
and 48 h (Fig. 3). The AMIS matured and later expended
into a lumen. E-cadherin staining in the WT cells was
absence or diffused at 3–6 h and showed signs of cell–cell
junctional pattern around 12 h. In TNS1-KO cells,
GP135 started to relocate forming an AMIS at 18 h and was
almost completely concentrated at the AMISs at 24 hr,
whereas cell–cell junctional E-cadherin could be detected at
6 h (Fig. 3). These results indicate that TNS1-KO cells can
still establish the apical-basal polarity and cell–cell junction,
and form AMIS, but AMIS in TNS1-KO cells develop
much faster than the WT cells and cannot ensure only one
AMIS is formed in each cyst. Altogether, our data suggest
that TNS1-KO 3D culture mimics the polycystic kidney
phenotype observed in TNS1-KO mice.
Cell–cell junctional localization of TNS1 is required for
rescuing multiple lumen phenotypes
To confirm the multiple lumen phenotype is due to lack
of TNS1 and to dissect the essential domain required,
GFP-TNS1 or tdTomato-TNS1 (Tom-TNS1) were trans-
fected into TNS1-KO MDCK cells to establish TNS1-KO/
GFP-TNS1 or TNS1-KO/Tom-TNS1 stable clones, which
were analyzed in 3D culture. Re-expression of
TNS1 significantly reduced multiple lumens and increased
single lumen cysts in 3D Matrigel (Fig. 4a). Since the
cell–cell junction is critical in lumenogenesis in MDCK
and TNS1 is also known to localize to cell–cell junctions10,
the significance of TNS1 cell–cell localization to lumen
formation was investigated. To this end, we first identified
domain/regions required for TNS1 cell–cell junction
localization with a series of mutants fused with tdTomato
(Fig. 4b–d). We found that (1) the shortest fragment
required is aa 882–1735, (2) the functional SH2 domain is
not required, (3) the functional PTB domain is needed,
and (4) aa 882–1032 region is essential for this subcellular
localization (Fig. 4c). We then generated a deletion mutant
Tom-TNS1Δ882–1032, which does not localize to
cell–cell junctions (Fig. 4c). Re-expression Tom-
TNS1Δ882–1032 in KO cells failed to rescue multiple
lumen phenotypes of KO cells (Fig. 4a). This demonstrates
the critical role of cell–cell junction localization of TNS1
in proper lumen formation in MDCK cells.
Upregulation of pMek is critical for multiple lumen
phenotype in MDCK TNS1-KO 3D culture
To understand the signaling pathways that may lead to
TNS1-KO phenotype, we took a candidate screening
Fig. 2 Loss of TNS1 leads to MDCK 3D cysts containing multiple lumens. a TNS1-WT or KO MDCK cells were seeded in Matrigel for 5 days and
then fixed for general morphology (bright field) or followed by immunofluorescence staining with Alexa Fluor 488 phalloidin for actin, anti-E-
cadherin, and anti-GP135 to detect the polarization patterns. b Overhead 3D reconstruction of confocal Z-stack images of representative WT and KO
3D cysts stained with phalloidin for F-actin. c Quantification of luminal phenotype populations displayed by TNS1-WT and KO MDCK cells (4
independent experiments with n > 80 cysts counted for each experiment), as well as d average cyst diameter (n > 20 cysts measured for each cell
line). P-values were calculated using two sample t-test. *P < 0.01, **P < 0.001. Scale bar= 10 μm.
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approach by immunoblotting. While the levels of pAkt,
Akt, pNFkB, NFkB, pGSKβ, GSKβ, and E-cadherin were
unaffected, pMek and pErk levels were consistently
upregulated in TNS1-KO MDCK 3D culture (Fig. 5a). To
demonstrate upregulated pMek was directly related to
loss of TNS1, pMek levels were examined in TNS1-KO/
GFP-TNS1 and TNS1-KO/tdTomato-TNS1 cells. Re-
expression of TNS1 in KO cells reduced pMek levels to
that of WT cells (Fig. 5b), indicating that enhanced Mek
activity is due to loss of TNS1 and may contribute to
multiple lumen phenotype in KO cells. In addition, the
Tom-TNS1Δ882–1032 mutant that did not localize to
cell–cell junctions (Fig. 4c) and did not rescue multiple
lumen phenotypes of KO cells (Fig. 4a) also could not
Fig. 3 TNS1-KO cells form multiple apical membrane initiation sites early during 3D culture. TNS1-WT or KO MDCK cells cultured in Matrigel
for 3, 6, 12, 18, 24 or 48 h were fixed and stained with GP135 and E-cadherin antibodies to detect polarization and cell–cell junction formations during
early cyst development. The experiments were repeated three times. Arrows show apical membrane initiation sites. Scale bar= 10 μm.
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Fig. 4 TNS1 localization to cell junctions is critical for single lumen formation. a Phenotypic quantification of MDCK KO/GFP, KO/GFP-TNS1, KO/
Tom-TNS1(tdTomato-TNS1) and KO/Tom-TNS1Δ882–1032 stable cell lines cultured in 3D Matrigel. *P < 0.01. b Schematic diagram of Tom-TNS1
mutants used for identification of primary sequences required for cell–cell localization and summary of localization results. The 1488m and 1625 m
mutants contain point mutations that inactive SH2 and PTB binding activities, respectively. c Representative live-cell images of MDCK cells
constitutively expressing GFP-actin cells transfected with indicated Tom-TNS1 mutants. Arrows point to cell–cell junctions. d Immunoblot analysis
confirmed the expression of expected molecular weights of indicated Tom-TNS1 mutants. Scale bar= 10 μm.
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inhibit the upregulated pMek (Fig. 5b), indicating that
cell–cell junction localization of TNS1 is required for
suppressing Mek activity. To further evaluate the role of
Mek activity, various Mek inhibitors were used to test
whether they could reverse multiple lumen phenotypes in
TNS1-KO MDCK. While U0126 (10 μM), trametinib
(0.01 μM), selumetinib (1 μM), CI-1040 (0.1 μM) rescued
the multiple lumen phenotypes, PD98059 (10 μM) treat-
ment showed no effect (Fig. 6). Interestingly, immuno-
blotting analysis confirmed that all inhibitors except
PD98059 were able to reduce levels of pErk, the
immediate target of Mek (Fig. 6). This may explain why
PD98059 treatment has no rescue effect.
pMek is upregulated in TNS1-KO kidneys and Mek
inhibitor treatment reduces disease burden in TNS1-KO
mice
Our studies using MDCK TNS1-KO cells have pointed
to a critical role of upregulated Mek activity as judged by
pS221-Mek levels (Fig. 5). To validate this finding in the
kidneys, kidney sections from 3-month old TNS1-WT or
KO mice were stained with pMek (S221), Mek, and pErk
(T202Y204) antibodies. In agreement with in vitro studies,
pMek and pErk levels were significantly increased in the
KO over the WT kidneys (Fig. 7, WT vehicle vs KO
vehicle). To further test whether Mek inhibitor treatment
may reduce the disease burden, we treated 3-month old
WT and KO mice with trametinib (1 mg/kg orally once a
day for 14 days), the most effective inhibitor shown in our
MDCK studies (Fig. 6). Kidneys were collected 4 days post
treatment and prepared for H&E and IHC staining assays.
With trametinib treatment, pMek and pErk levels were
reduced, and signs of interstitial infiltrates, fibrosis and
dilated tubules were significantly improved in TNS1-KO
kidneys (Fig. 7). These results not only validate our
in vitro findings but also provide a potential therapeutic
strategy using Mek inhibitors for cystic kidney diseases.
Discussion
In this report, we have established a 3D MDCK TNS1-
KO cell system, which develops into cysts with multiple
lumens that mimic cystic kidney defects observed in
TNS1 knockout mice. This in vitro system allows us to
further identify the critical roles of a TNS1 fragment (aa
882–1032) that is required for TNS1′s cell–cell junction
localization, for suppression of the Mek/Erk activities, and
for rescuing the multiple lumen phenotype.
Cell–cell junctions play important roles in kidney
morphogenesis and functions. In MDCK cells, down-
regulation of adherens junction molecule such as E-cad-
herin, or tight junction molecules including ZO1 or ZO2
Fig. 5 The Mek/Erk pathway is upregulated in TNS1KO 3D cysts.
a Total cell lysates isolated from 5-day 3D cultures of MDCK TNS1-WT
or KO (a) or KO/GFP, KO/G(FP)-TNS1, KO/T(omato)-TNS1, KO/T(omato)-
TNS1 Δ882-1029 (b) were immunoblotted (IB) with indicated
antibodies. The studies were repeated at least three times.
Fig. 6 Multiple lumen phenotype in TNS1-KO MDCK cells is
reversed by Mek inhibitor treatments. MDCK TNS1-KO cells
cultured in 3D matrigel together with indicated reagents for 5 days
were analyzed for the populations of single, multiple, and filled
lumens (upper panel) or for immunoblotting with pErk1/2, Erk1/2, or
GAPDH antibodies (lower panel). The experiments were
independently repeated three times. Note that all Mek inhibitors
except PD98059 rescued KO lumen phenotypes with trametinib to be
the most effective. P-values were calculated using two sample t-test.
*P= 0.02, #P < 0.01.
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Fig. 7 Mek inhibitor treatment reduced the levels of upregulated pMek, pErk, interstitial infiltrates, tubular dilations, and fibrosis in TNS1-
KO kidneys. TNS1-WT or KO male C57 mice (N= 4, each group) at 3-month-old were treated with trametinib (1 mg/kg) or vehicle for 14 days.
Kidneys were harvested 4 days post-treatment and processed for H&E, IHC staining using pMek1/2(pS221), Mek1/2, or Erk(pT202pY204) antibodies,
and Sirius Red staining for collagen. Interstitial infiltration and IHC signals were quantified for statistical analysis shown on the left panel. Note that
levels of pMek and pErk, and signs of interstitial infiltrates, fibrosis and dilated tubules were significantly reduced in TNS1-KO kidneys treated with
trametinib. Arrows show dilated tubules. Arrowhead indicates interstitial infiltrates. Scale bars= 50 μm in Sirius Red, or 100 μm in others. P-values
were calculated using two sample t-test. ***P < 0.0001.
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lead to compromised 3D cysts with multiple lumens28–30
similar to those of TNS1-KO cysts. These findings clearly
demonstrate the critical role of cell–cell junction in
lumenogenesis. It is known that knockdown of E-cadherin
activates Mek/Erk signaling and promotes epithelial-
mesenchymal transition (EMT)31. Cleavage of E-
cadherin also enhances Mek pathway32. Although the
cell junction localization and protein level of E-cadherin
appear to be normal in TNS1-KO cysts (Figs. 2a and 5a), it
is possible that cell junction localization of TNS1 may
suppress Mek/Erk signaling through stabilizing the
integrity of cell–cell junction.
Although our current studies have demonstrated the
essential role of cell–cell junction localization in directing
the single luminal development, the potential contribu-
tion of TNS1′s focal adhesion localization in this process
has not been ruled out. Because TNS1 contains at least
two independent focal adhesion targeting sites, one
overlapping with an actin-binding region and the other
within the SH2 and PTB domains33, it is more challenging
to dissect their direct involvement in the multiple lumen
phenotype. Nonetheless, we are continuing to study the
possibility.
Upregulation of Mek/Erk activities appear to be critical
for developing multiple lumen phenotypes in TNS1-KO
cells, since Mek inhibitor treatments could rescue the
phenotypes. This finding not only prompted us to
examine pMek/pErk levels in TNS1-KO kidneys but also
to investigate the potential therapeutic effects of using
Mek inhibitors in TNS1-KO mice. Our current studies
indicate that trametinib treatment is able to reduce
pathogenesis of TNS1-KO kidneys in the early stage. Long
term beneficial effects and optimal treatment regimen
warrant further investigation. Interestingly, upregulation
of Mek/Erk activity is also detected in the cystic kidneys of
polycystin-1 knockout mice and polycystin-2 transgenic
mice34–38. Additionally, primary cell cultures from human
ADPKD kidneys also display upregulated Erk activities34.
Previously, Mek inhibitors were used to treat PKD mouse
models. While PD184352 treatment slows polycystic
kidney progression in pcy mice38, U0126 treatment shows
no effect on progression of cyst formation in the PKD1
model35. Whether the discrepancy is due to using differ-
ent kinds of inhibitors and/or mouse models require
further investigation. Nonetheless, with our findings,
targeting the Mek/Erk pathway remains a promising
therapeutic approach for cystic kidney diseases.
Currently, there is no known human cystic kidney
patient that is caused by TNS1 mutation. Nonetheless,
because TNS1-KO mice develop cystic phenotypes pro-
gressively, are fertile, and live almost half of the normal
mouse lifespan, it is very likely that a group of human
cystic kidney patients display similar symptoms caused by
mutations or aberrant expression of TNS1. These patients
are also likely to suffer from mitral valve prolapse (MVP)
and/or chronic obstructive pulmonary disease (COPD),
since TNS1 is a high-risk gene for both health issues
identified through genome-wide association studies
(GWAS)24,39,40. We are in the process of collecting and
sequencing patient samples to test this possibility.
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